| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer th...
Goldman Sachs analyst Salveen Richter initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and announces Price Tar...
Craig-Hallum analyst Adam Vogel initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and announces Price Target of...
Guggenheim analyst Michael Schmidt reiterates Immunome (NASDAQ:IMNM) with a Buy and maintains $25 price target.